Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 14, 2006; 12(22): 3602-3608
Published online Jun 14, 2006. doi: 10.3748/wjg.v12.i22.3602
Published online Jun 14, 2006. doi: 10.3748/wjg.v12.i22.3602
Table 2 Immunoprofiles of the groups studied (mean ± SD)
| Immuno-markers | Stage A | Stage B | Lymphoma | Normal |
| Syndecan-1 | 69 ± 3.40 | 51 ± 10.25 | 10.1 ± 6.354 | 11 ± 7.605 |
| bcl6 | 1.75 ± 1.63 | 3.64 ± 3.541 | 4.25 ± 4.152 | 0.55 ± 0.51 |
| p53 | 3.15 ± 3.257 | 6.5 ± 2.914 | 9.2 ± 4.315 | 0.11 ± 0.901 |
| κ light chain | 67.51 ± 16.952 | 67.42 ± 18.95 | 55 ± 2.399 | 42 ± 13.475 |
| λ light chain | 35 ± 13.857 | 24 ± 1.346 | 25.5 ± 1.087 | 29 ± 12.356 |
| IgA heavy chain | 72 ± 4.570 | 62 ± 24.521 | 22 ± 2.972 | 36 ± 6.513 |
- Citation: Vaiphei K, Kumari N, Sinha SK, Dutta U, Nagi B, Joshi K, Singh K. Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease. World J Gastroenterol 2006; 12(22): 3602-3608
- URL: https://www.wjgnet.com/1007-9327/full/v12/i22/3602.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i22.3602